# Cure51

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cure51

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.cure51.com/
- Total disclosed funding: $8.2M
- Latest round: Seed (Mar 14, 2024)
- Investors on record: 4

## About

Founded in 2021 and based in Paris, France, Cure51 operates as a provider of a database for cancer survivors to examine causes and cures. Nicolas Wolikow (CEO) and Simon Istolainen (CSO) are the co-founders of the company. In March 2024, Cure51 raised EUR 15 million in seed funding led by Sofinnova Partners, including Itachi Ventures and Life Extension Ventures.

The company provides its discovery platform, which is a system designed to organize, analyze, and discover therapeutic targets. The firm’s platform builds a comprehensive clinical and multi-omics database of outliers worldwide. Cure51 discovers multimodal signs and develops medicine tools that provide actionable insights for therapeutic discovery in partnership with scientific partners and computational biology.

The organization plans to use the March 2024 funding to support its growth and solutions.

## Funding rounds

- Seed, Mar 14, 2024, $8.2M — Sofinnova Partners, Kima Ventures, Hitachi Ventures, Life Extension Ventures

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed
- Kima Ventures (https://capitalatlas.ai/funds/kima-ventures) — Seed
- Hitachi Ventures (https://capitalatlas.ai/funds/hitachi-ventures) — Seed
- Life Extension Ventures (https://capitalatlas.ai/funds/life-extension-ventures) — Seed